With the new financing, Kallyope plans to move its pipeline programs toward the clinic and hire another 16 people.

John Davis, who headed early clinical development at Pfizer, joined Magenta Therapeutics.

Medigene has been given a green light in Germany to start human trials of MDG1011, the lead candidate to come out of its modified T-cell program.

The French biopharma follows Fosun, Takeda and UCB to become the fourth company to secure a connection to Arix’s stable of startups.

Ionis could pick up $300 million in milestones and royalties as well as the $30 million licensing fee.

AbbVie has teamed with Voyager Therapeutics on a tau protein-targeting program, paying $69 million for an option on the Alzheimer’s disease candidate.

Perennial biotech dealmaker Takeda is at it again, striking a new pact with Wave Life Sciences with a focus on a series of neurological disorders.

Aimmune plans to file for FDA approval by the end of 2018 to give patients a way to protect themselves against accidental exposure to peanut protein.